Hoth Therapeutics Announces HREC Approval In Australia For The Next Phase Of Its Trial Of Biolexa For Patients With Atopic Dermatitis
June 21 (Reuters) - Hoth Therapeutics Inc (HOTH.O) :
* HOTH THERAPEUTICS ANNOUNCES HREC APPROVAL IN AUSTRALIA FOR THE NEXT PHASE OF ITS TRIAL OF BIOLEXA FOR PATIENTS WITH ATOPIC DERMATITIS
The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: email@example.com